GlassScriptPhysician profile
Thomas K Mckean
NPI 1841359486
$16,420.94
in general payments reported to CMS, 2019-2025
39 companies · $2,936 in 2025
The $2,936 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,376 · 2020: $2,149 · 2021: $2,395 · 2022: $2,270 · 2023: $2,624 · 2024: $2,671 · 2025: $2,936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,218 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,218.30 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,518.97 | 2020-2025 | Caplyta |
| Alkermes, INC. | $1,456.47 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Bausch Health US, LLC | $1,351.82 | 2019-2025 | Aplenzin, Wellbutrin |
| Neurocrine Biosciences, INC. | $1,317.03 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $1,261.66 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $1,034.63 | 2019-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Sunovion Pharmaceuticals INC. | $1,013.29 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $956.58 | 2019-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $864.63 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $823.58 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Axsome Therapeutics, INC. | $697.34 | 2022-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $604.81 | 2019-2025 | Rexulti |
| Abbvie INC. | $558.72 | 2021-2025 | |
| Corium, LLC | $495.74 | 2021-2024 | Azstarys |
| Acadia Pharmaceuticals INC | $325.47 | 2019-2024 | Nuplazid |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $286.66 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $285.36 | 2022-2024 | Quviviq |
| Indivior INC. | $222.84 | 2023-2024 | Perseris |
| Eisai INC. | $191.30 | 2020-2021 | |
| Allergan, INC. | $177.59 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $152.37 | 2019-2021 | |
| Noven Therapeutics, LLC | $131.84 | 2021-2025 | Xelstrym, Secuado |
| Tris Pharma INC | $125.41 | 2019-2025 | Dyanavel Xr |
| Novo Nordisk INC | $85.21 | 2019-2023 | Wegovy |
| Merck Sharp & Dohme LLC | $73.12 | 2020-2021 | |
| Neos Therapeutics, LP | $70.39 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $44.33 | 2019-2022 | |
| Adlon Therapeutics L.P. | $39.37 | 2019-2020 | |
| Luye Pharma (USA) LTD. | $27.59 | 2025 | Erzofri Extended-Release |
| Pfizer INC. | $27.54 | 2025 | |
| Almatica Pharma LLC | $26.55 | 2021 | |
| Neuronetics, INC. | $25.53 | 2019-2020 | |
| Alfasigma USA, INC. | $24.93 | 2022 | |
| Supernus Pharmaceuticals, INC. | $24.19 | 2025 | Qelbree |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.84 | 2025 | Rexulti |
| Bioxcel Therapeutics, INC. | $21.67 | 2023 | Igalmi |
| Lilly USA, LLC | $19.60 | 2025 | Kisunla, Amyvid |
| Sun Pharmaceutical Industries INC. | $19.42 | 2021 | |
| Shire North American Group INC | $14.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mckean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.